Prediction of Disease ProgressionNCT07292116
Disease Progression in ms
An observational study of Prediction of Disease Progression and Multiple Sclerosis, run by Hüseyin Bektaş.
Trial summary
Demographic and clinical data will be obtained from people with MS. Based on this data, the progression of the disease will be predicted with artificial intelligence. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Prediction of Disease Progression, Multiple Sclerosis
- How many people
- 53 participants
- Where
- No sites listed yet
- Study dates
- 15 Dec 2025to 1 Mar 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: MS patients coming to Tatvan State Hospital
Who may be able to join
- Having been diagnosed with MS
Who cannot join
- be literate
About this study
Official title: Prediction of Disease Progression Using Machine Learning Based on Clinical Data in People With Multiple Sclerosis
Demographic and clinical data will be obtained from people with MS. Based on this data, the progression of the disease will be predicted with artificial intelligence.
Read the detailed description
Demographic and clinical data will be obtained from people with MS. Demographic data; age, gender, disease type, disease duration. Clinical data; Frailty, Physical Activity Level, Walking, Balance, Fatigue, Quality of Life. Based on these data, disease progression will be predicted with artificial intelligence and motor learning.
- Keywords
- Multiple sclerosis (MS), artificial intelligence, motor learning
- Medical subject headings
- Multiple Sclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| intervention group | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Fragility level
The level of frailty will be measured by the Frailty Index.
Measured: 3 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Dec 2025
- Study start15 Dec 2025 (estimated)
- Primary completion20 Dec 2025 (estimated)
- Study completion1 Mar 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prediction of Disease ProgressionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 53 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hüseyin Bektaş
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Hüseyin Bektaş, Pamukkale University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07292116
- Sponsor's protocol ID
- 53513060613
- Status last verified
- Dec 2025
- First submitted
- 12 Mar 2025
- Last updated
- 18 Dec 2025
- Results posted
- No
- Individual data sharing
- No: The results of the study will be announced
Study at a glance
From the registry record, last updated by the sponsor on 18 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prediction of Disease Progression Using Machine Learning Based on Clinical Data in People With Multiple Sclerosis
- ClinicalTrials.gov ID
- NCT07292116
- Acronym / sponsor ID
- 53513060613
- Keywords
- Multiple sclerosis (MS), artificial intelligence, motor learning
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 53 participants (estimated)
- Lead sponsor
- Hüseyin BektaşUniversity, hospital or other
- Study start
- 15 Dec 2025 (estimated)
- Primary completion
- 20 Dec 2025 (estimated)
- Study completion
- 1 Mar 2026 (estimated)
- First posted
- 18 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Demographic and clinical data will be obtained from people with MS. Based on this data, the progression of the disease will be predicted with artificial intelligence.
Detailed description
Demographic and clinical data will be obtained from people with MS. Demographic data; age, gender, disease type, disease duration. Clinical data; Frailty, Physical Activity Level, Walking, Balance, Fatigue, Quality of Life. Based on these data, disease progression will be predicted with artificial intelligence and motor learning.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| intervention group | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- MS patients coming to Tatvan State Hospital
Key inclusion criteria (1 listed)
- Having been diagnosed with MS
Key exclusion criteria (1 listed)
- be literate
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Fragility level
Time frame: 3 month
The level of frailty will be measured by the Frailty Index.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Dec 2025.
- Individual participant dataSharing planned: No. The results of the study will be announced
Related trials for Prediction of Disease Progression
RecruitingObservational study
Belgian Lung Function Study
Chronic Respiratory Diseases
RecruitingObservational study
A Prospective Cohort Study of Multimodal Biomarkers and Progression From Mild Cognitive Impairment to Dementia
Mild Cognitive Impairment (MCI)
RecruitingObservational study
Repeated Examinations for Typing Pulmonary Embolism
Pulmonary Embolism (Diagnosis), Pulmonary Embolism Acute
Not yet recruitingObservational study
Gait Pattern and Its Relation to Cognition and VEP in Multiple Sclerosis
Multiple Sclerosis, Gait Disorders, Neurologic
Enrolling by invitationObservational study
Multimodal Digital Biomarker Prediction of Acute Clinical Deterioration
Acute Disease, Disease Progression
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Prediction of Disease Progression and Multiple Sclerosis, run by Hüseyin Bektaş.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 18 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Fragility level (time frame: 3 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Dec 2025.